A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy

Trial Profile

A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs CC 11050 (Primary)
  • Indications Cutaneous lupus erythematosus
  • Focus Adverse reactions
  • Acronyms APHRODITE
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 May 2017 Status changed from recruiting to completed.
    • 17 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top